Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis

Annals of Internal Medicine

Volumn 114, Issue 6, 1991, Pages 437-444

  Epstein, Wallace V ^a   Henke, Curtis J ^a   Yelin, Edward H ^a   Katz, Patricia P ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD SALT;

ADULT; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS, GOLD; ARTHRITIS, RHEUMATOID; FEMALE; HUMAN; INTERVIEWS; JOINTS; MALE; MIDDLE AGE; MULTIVARIATE ANALYSIS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PAIN; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026078624     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-114-6-437     Document Type: Article

References (34)

1. The Research Sub-Committee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: report of a multi-centre controlled trial. Ann Rheum Dis. 1960;19:95-119.
2. The Research Sub-Committee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis. Ann Rheum Dis. 1961;20:315-40.
3. Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med. 1974;80:21-6.
4. Ward JR, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1983;26:1303-15.
5. Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum. 1988;31:702-13.
6. Kushner I. Does aggressive therapy of rheumatoid arthritis affect outcome? J Rheumatol. 1989;16:1-4.
7. Epstein WV. Parenteral gold therapy for rheumatoid arthritis: a treatment whose times has gone [Editorial]. J Rheumatol. 1989;16: 1291-4.
8. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-72.
9. Iannuzzi L, Dawson N, Zein N, Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 1983;309:1023-8.
10. Gabriel SE, Luthra HS. Rheumatoid arthritis: can the long-term outcome be altered. Mayo Clin Proc. 1988;63:58-68.
11. Sharp JT, Lidsky MD, Duffy J. Clinical responses during gold therapy for rheumatoid arthritis. Changes in synovitis, radiologically detectable erosive lesions, serum proteins, and serologic abnormalities. Arthritis Rheum. 1982;25:540-9.
12. Gordon DA. Gold compounds. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 3d ed. Philadelphia: W.B. Saunders Co.; 1989:804-23.
13. Bye B, Schechter E. 1978 Survey of Disability and Work: Technical Introduction Washington, D.C.: U.S. Department of Health and Human Services, Social Security Administration, Office of Policy, Office of Research and Statistics; 1982:1-12. SSA publication number 13-11745.
14. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol. 1988;15:1480-8.
15. Yelin EH, Henke CJ, Kramer JS, Nevitt MC, Shearn M, Epstein WV. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med. 1985;312:962-7.
16. Nevitt MC, Yelin EH, Henke CJ, Epstein WV. Risk factors for hospitalization and surgery in patients with rheumatoid arthritis: implications for capitated medical payment. Ann Intern Med. 1986; 105:421-8.
17. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1987;30:507-12.
18. Arellano MG, Petersen GR, Petitti DB, Smith RE. The California Automated Mortality Linkage System (CAMLIS). Am J Public Health. 1984;74:1324-30.
19. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity [Editorial]. J Rheumatol. 1986;13:841-5.
20. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-30.
21. Oreglia A. Abridged life tables for California 1985. Sacramento, California: Department of Health Services, Data Retrieval and Analysis Section; 1986.
22. Sherrer YS, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumatol. 1987;14:705-9.
23. van der Heijde DM, van Riel PL, van Rijswijk MH, van de Putte LB. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum. 1988; 17:284-92.
24. Ragan C. Rheumatoid arthritis. Bull N Y Acad Med. 1951;27:63-74.
25. Wolfe F. 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol. 1990;22(Suppl):24-32.
26. Bradley LA. Psychosocial factors and disease outcomes in rheumatoid arthritis: old problems, new solutions and a future agenda [Editorial]. Arthritis Rheum. 1989;32:1611-4.
27. Bombardier C, Tugwell P, Sinclair A, et al. Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol. 1982;9:798-806.
28. Anderson JJ, Felson DT, Meenan RF, Williams HJ. Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum. 1989;32:1093-9.
29. Anderson JJ, Firschein HE, Meenan RF. Sensitivity of a health status measure to short-term clinical changes in arthritis. Arthritis Rheum. 1989;32:844-50.
30. Yelin E, Lubeck D, Holman H, Epstein W. The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. J Rheumatol. 1987;14:710-7.
31. Meenan RF, Kazis LE, Anderson JJ. The stability of health status in rheumatoid arthritis: a five-year study of patients with established disease. Am J Public Health. 1988;78:1484-7.
32. Louis TA. General methods for analyzing repeated measures. Stat Med. 1988;7:29-45.
33. Bombardier C, Tugwell P. Controversies in the analysis of long-term clinical trials of slow acting drugs [Editorial]. J Rheumatol. 1985; 12:403-5.
34. Goldman AE, McDonald SS. Practices, strategies, and motivations in treatment of rheumatoid arthritis. Am J Med. 1983;75:79-85.